Academic Background Glioblastoma (GBM) is one of the most aggressive and heterogeneous central nervous system tumors, with an extremely poor prognosis. Despite the emergence of novel therapies such as anti-angiogenic treatments and immunotherapy in recent years, the survival period of GBM patients remains very limited. GBM cells exhibit unique meta...